



ATTORNEY DOCKET No.: 2003946-0049 (OP1254-US)

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Applicant:	Imai, et al.	Examiner:	Vandervegt, Francois P.
Serial No.:	09/963,316	Art Unit:	1644
Filing Date:	September 25, 2001		
Title:	USES OF ANTI-CX3CR1 ANTIBODY, ANTI-FRACTALKINE ANTIBODY AND FRACTALKINE		

Mail Stop RCE  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

**Certificate of Mailing**

I certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as First Class Mail in an envelope addressed to Mail Stop RCE, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

April 1, 2005

Date

Signature

Beatrice M. Aveline, Ph.D.

Typed or Printed Name of person signing certificate

Sir:

**SUBMISSION UNDER 37 C.F.R. § 1.111 AND § 1.114**

In response to the Final Office Action mailed October 4, 2004, Applicant respectfully requests consideration of the following amendments and remarks in conjunction with the Request for Continued Examination filed herewith. A Shortened Statutory Period was set to expire three (3) months after the mailing date of the Final Office Action, i.e. on January 4, 2005. Applicant hereby requests a three (3) month extension of time extending the time for reply to and including April 4, 2005. Therefore, Applicant respectfully submits that the filing of this RCE on April 1, 2005 is timely.

Applicant requests entrance of the following Amendment and consideration of the following Remarks. **Amendments to the Claims** are reflected in the listing of the claims which begins on page 2 of this paper. **Remarks** begin on page 5 of this paper.

The present Amendment is believed to be in compliance with the Revised Amendment Format published in the Federal Register on June 30, 2003 (68 FC 38611), and therefore to be exempt from the requirement of 37 C.F.R. § 1.121(a)-(d).